BSI Life Sciences announces it has been awarded a SaaS agreement by global contract research organization HEMEX to provide its comprehensive eClinical platform for clinical trials, BSI CTMS with integrated eTMF (electronic Trial Master File). Founded in Switzerland in 2015, HEMEX has provided expert project management for clinical trials and regulatory services to Pharma, MedTech and IVD companies, as well as support with non-dilutive funding opportunities to healthcare startups. With numerous active projects, in early 2023 it became clear to its Management Board that implementing an eClinical system would be critical to support the growing scale of operations. “While on the lookout for a CTMS with eTMF, we were recommended BSI Life Sciences by our longtime partner and trusted EDC (Electronic Data Capture) provider, Greenlight Guru,” recalls Chief Commercial Officer at HEMEX Dr. Mohamed Hussien. “This is when we learned that BSI’s CTMS software integrates out-of-the-box with the EDC system we had been using for years. We immediately knew it was the right solution for us,” continues Dr. Hussien. BSI’s eClinical platform allows for the seamless integration and management of studies, trial sites, contacts, and subjects – all in one place. And, in the words of its manufacturer, it evolves with its clients: “BSI CTMS is never static. We listen to our users’ feedback and release a major upgrade to the software including new modules or features once a year. And all this is free for our SaaS customers,” explains BSI’s Community Manager Life Sciences Jan Nielsen.
When selecting BSI Life Sciences as its CTMS provider, HEMEX also decided to join the attractive BSI’s referral program, which grants its members a discount on the SaaS fee and additional benefits, such as joint marketing campaigns and the participation in client webinars and on-site events. Commenting on the partnership with the software house, the Co-Founder and CEO of HEMEX Pascal Winnen highlights the importance of building effective ecosystems in the clinical trial space: “By partnering with expert service providers and key opinion leaders, we can join forces and combine expertise in different areas. This eventually translates into quicker and higher-quality results for everyone involved”. “We’re thankful to BSI Life Sciences for the opportunity to become part of its community of likeminded businesses in the clinical research industry,” adds Winnen. BSI’s Nielsen is confident HEMEX “will be a fantastic ambassador for BSI’s digital solutions, also thanks to its extensive market presence in the US and the EU region. We couldn't be more excited about this collaboration.” HEMEX is targeted to go live with BSI CTMS in Q1 2024, after a training session for its administrator users will have taken place at its Swiss headquarters near Basel in January.
About HEMEX
Founded in 2015 as a healthcare management expert CRO, HEMEX provides services ranging from Study Start-Up to Clinical Monitoring, from Regulatory Submission to Pharmacovigilance to Pharma, Biotech and MedTech companies. Further, it supports early-stage life science start-ups with granting opportunities and fundraising workshops. Incorporated in Switzerland in 2015, HEMEX has been steadily growing and now also has offices in Germany, Belgium, and the US. Its team has been involved with over 180 projects worldwide.
For more information, please visit: www.hemex.ch
When selecting BSI Life Sciences as its CTMS provider, HEMEX also decided to join the attractive BSI’s referral program, which grants its members a discount on the SaaS fee and additional benefits, such as joint marketing campaigns and the participation in client webinars and on-site events. Commenting on the partnership with the software house, the Co-Founder and CEO of HEMEX Pascal Winnen highlights the importance of building effective ecosystems in the clinical trial space: “By partnering with expert service providers and key opinion leaders, we can join forces and combine expertise in different areas. This eventually translates into quicker and higher-quality results for everyone involved”. “We’re thankful to BSI Life Sciences for the opportunity to become part of its community of likeminded businesses in the clinical research industry,” adds Winnen. BSI’s Nielsen is confident HEMEX “will be a fantastic ambassador for BSI’s digital solutions, also thanks to its extensive market presence in the US and the EU region. We couldn't be more excited about this collaboration.” HEMEX is targeted to go live with BSI CTMS in Q1 2024, after a training session for its administrator users will have taken place at its Swiss headquarters near Basel in January.
About HEMEX
Founded in 2015 as a healthcare management expert CRO, HEMEX provides services ranging from Study Start-Up to Clinical Monitoring, from Regulatory Submission to Pharmacovigilance to Pharma, Biotech and MedTech companies. Further, it supports early-stage life science start-ups with granting opportunities and fundraising workshops. Incorporated in Switzerland in 2015, HEMEX has been steadily growing and now also has offices in Germany, Belgium, and the US. Its team has been involved with over 180 projects worldwide.
For more information, please visit: www.hemex.ch
